New

Global ETF Survey 2026: Answer now →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
ETF IssuersHANetfWELL
WELL

Harbor Health Care UCITS ETF

The WELL Exchange Traded Fund (ETF) is provided by HANetf. This fund is actively managed; it does not track an index. The dividend policy is capitalization.

Advertisement

$8.46
-$0.033 (-0.39%) today
9:52 AM 08/18/26 Open
1D price range
$8.44$8.46
52W price range
$6.92$8.61
YTD Perf.
+6.39%
YTD Flows
Annualized volatility
Fund AuM
€13M
Share class AuM
€13M
TTM Yield
-
Tracking Error
Tracking Difference
ISIN
IE00BJQTJ848
TER
0.89%
Inception date
4/4/2019
Issuer
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Aug 17, 2026
-10%-5%0%5%10%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
99.00%
Unavailable
1.00%
Latest WELL news

FAQ about WELL

WELL is a Active ETF. This ETF provides exposure to Other US Health Care Equities.
WELL carries a total expense ratio (TER) of 0.89%, indicating the annual cost for holding the fund.
WELL was introduced to the market on April 4, 2019. It trades on Austria, among other exchanges
Harbor Health Care UCITS ETF, WELL, is provided by HANetf. Learn more about HANetf here.
WELL oversees €13M in assets as of August 17, 2026.
WELL follows a capitalizing, meaning it reinvests income within the fund.
As of June 30, 2026, WELL has significant geographic allocations in USA, Denmark and France.
As of June 30, 2026, WELL focuses largely on Healthcare.
As of June 30, 2026, WELL holds 39 positions in its portfolio, with 68.71% of assets concentrated in its top 15 holdings.
As of June 30, 2026, WELL top three holdings include Ascendis Pharma A/S, Eli Lilly & Co. and Rhythm Pharmaceuticals, Inc..
The base currency of WELL is USD.
Data as of 06/30/26
Ascendis Pharma A/S
9.08%
Eli Lilly & Co.
8.75%
Rhythm Pharmaceuticals, Inc.
5.55%
Legend Biotech Corp.
4.90%
Natera, Inc.
4.82%
Revolution Medicines, Inc.
4.43%
Gilead Sciences, Inc.
4.43%
Insmed, Inc.
4.02%
AbbVie, Inc.
3.94%
UnitedHealth Group, Inc.
3.70%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight